Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 78

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 78
---
 (1)(102)— (102)   Foreign currency translation adjustments— 3,882 3,882 Balance at September 30, 2025$88 $4,035 $4,123 Net Unrealized Gain From Available-For-Sale InvestmentsUnrealized Foreign Currency TranslationAccumulated Other Comprehensive IncomeBalance at December 31, 2023$124 $123 $247    Net unrealized gain on investments, net of tax (1)437 — 437    Foreign currency translation adjustments— (6)(6)Balance at September 30, 2024$561 $117 $678 (1) Net of a nominal and $0.1 million tax benefit for the nine months ended September 30, 2025 and 2024, respectively. Share Repurchase ProgramsOn May 7, 2024, the Company announced that its Board of Directors approved a share repurchase program which authorized the Company to repurchase up to an aggregate of $150.0 million of its outstanding common stock. On May 9, 2024, concurrently with the pricing of the offering of the 2029 Notes, the Company entered into separate privately negotiated agreements with certain of the initial purchasers of the 2029 Notes or their respective affiliates and/or certain other financial institutions to repurchase 837,240 shares of the Company’s common stock for a total cost of $25.1 million, inclusive of $0.1 million of accrued excise tax. The repurchase occurred on May 10, 2024.On April 17, 2025, the Company announced that its Board of Directors approved a new share repurchase program, which replaced the previously authorized share repurchase program and was effective immediately, which authorizes the Company to repurchase up to an aggregate of $300.0 million of its outstanding common stock. Repurchases under this program may be made at management’s discretion on the open market or through privately negotiated transactions, including plans that comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The share repurchase program may be suspended or 

Pacira BioSciences, Inc.  |  Q3 2025 Form 10-Q  |  25

discontinued at any time by the Company and has an expiration date of December 31, 2026. During the nine months ended September 30, 2025,